RU2019126797A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019126797A3 RU2019126797A3 RU2019126797A RU2019126797A RU2019126797A3 RU 2019126797 A3 RU2019126797 A3 RU 2019126797A3 RU 2019126797 A RU2019126797 A RU 2019126797A RU 2019126797 A RU2019126797 A RU 2019126797A RU 2019126797 A3 RU2019126797 A3 RU 2019126797A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653539P | 2012-05-31 | 2012-05-31 | |
| US61/653,539 | 2012-05-31 | ||
| US201361787686P | 2013-03-15 | 2013-03-15 | |
| US61/787,686 | 2013-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014152031A Division RU2699358C2 (ru) | 2012-05-31 | 2013-05-29 | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019126797A RU2019126797A (ru) | 2019-10-07 |
| RU2019126797A3 true RU2019126797A3 (ru) | 2020-02-25 |
| RU2759837C2 RU2759837C2 (ru) | 2021-11-18 |
Family
ID=49674030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014152031A RU2699358C2 (ru) | 2012-05-31 | 2013-05-29 | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора |
| RU2019126797A RU2759837C2 (ru) | 2012-05-31 | 2013-05-29 | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014152031A RU2699358C2 (ru) | 2012-05-31 | 2013-05-29 | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10098892B2 (ru) |
| EP (1) | EP2854816B1 (ru) |
| JP (1) | JP6263169B2 (ru) |
| KR (1) | KR102123130B1 (ru) |
| CN (2) | CN104321059A (ru) |
| AU (2) | AU2013267613A1 (ru) |
| BR (1) | BR112014025041B8 (ru) |
| MX (1) | MX368859B (ru) |
| RU (2) | RU2699358C2 (ru) |
| WO (1) | WO2013181174A2 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2699358C2 (ru) * | 2012-05-31 | 2019-09-05 | Мерк Шарп И Доум Корп. | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора |
| JP6737708B2 (ja) * | 2014-04-17 | 2020-08-12 | サンド・アクチエンゲゼルシヤフト | オレキシン受容体拮抗薬を含む固体分散体 |
| WO2015164160A1 (en) * | 2014-04-21 | 2015-10-29 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
| WO2015180060A1 (zh) * | 2014-05-28 | 2015-12-03 | 杭州普晒医药科技有限公司 | 一种二氮杂环庚烷化合物的盐及其晶型与无定型物 |
| EP3223803A1 (en) * | 2014-11-24 | 2017-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases |
| CZ201587A3 (cs) | 2015-02-10 | 2016-08-17 | Zentiva, K.S. | Amorfní pevná forma suvorexantu s kyselinou sírovou |
| WO2017001499A1 (en) | 2015-06-30 | 2017-01-05 | Hexal Ag | Liquid composition comprising suvorexant |
| WO2017072264A1 (en) | 2015-10-29 | 2017-05-04 | Hexal Ag | Solid composition comprising suvorexant |
| CN105886592A (zh) * | 2016-03-02 | 2016-08-24 | 昆明理工大学 | 一种基于食欲素受体1分子探针的药物活性成分筛选方法 |
| WO2017194548A1 (en) * | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
| JP2020502144A (ja) * | 2016-12-19 | 2020-01-23 | ドラッガビリティー テクノロジーズ アイピー ホールディング カンパニー リミテッドＤｒｕｇｇａｂｉｌｉｔｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｐ Ｈｏｌｄｃｏ Ｌｉｍｉｔｅｄ | スボレキサントの医薬製剤 |
| BR112019021324A2 (pt) * | 2017-04-13 | 2020-06-16 | Paul Remon Jean | Composições baseadas em xanthohumol |
| US11504327B1 (en) | 2019-01-21 | 2022-11-22 | Eric Morrison | Method of preparing nanoparticles by hot-melt extrusion |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3222359A (en) | 1965-12-07 | Process for preparing benzodiazepine compounds | ||
| MXPA02006324A (es) * | 1999-12-23 | 2002-12-13 | Pfizer Prod Inc | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco. |
| EP1401503B1 (en) * | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
| CN1787808A (zh) * | 2002-02-01 | 2006-06-14 | 辉瑞产品公司 | 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法 |
| JP2009514884A (ja) * | 2005-11-04 | 2009-04-09 | イーストマン ケミカル カンパニー | 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル |
| RU2457841C2 (ru) * | 2006-02-09 | 2012-08-10 | Мерк Шарп Энд Домэ Корп. | Полимерные композиции ингибиторов сетр |
| JP2009531447A (ja) | 2006-03-29 | 2009-09-03 | メルク エンド カムパニー インコーポレーテッド | ジアゼパンオレキシン受容体アンタゴニスト |
| PE20081229A1 (es) * | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| JP2010526848A (ja) * | 2007-05-11 | 2010-08-05 | エフ．ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| MX2010007645A (es) * | 2008-01-11 | 2010-11-05 | Cipla Ltd | Forma de dosis farmaceutica solida. |
| US7902376B2 (en) | 2008-01-23 | 2011-03-08 | Merck Sharp & Dohme Corp. | Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates |
| EP2680697B1 (en) | 2011-03-03 | 2018-01-10 | Merck Sharp & Dohme Corp. | Process for the preparation of an orexin receptor antagonist |
| RU2699358C2 (ru) * | 2012-05-31 | 2019-09-05 | Мерк Шарп И Доум Корп. | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора |
| KR20150097486A (ko) | 2012-11-12 | 2015-08-26 | 닥터 레디스 레보러터리즈 리미티드 | 수보렉산트의 다형태 |
| WO2015008218A2 (en) | 2013-07-15 | 2015-01-22 | Dr. Reddy’S Laboratories Limited | Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant |
| US20160346198A1 (en) | 2014-02-05 | 2016-12-01 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| CN103923068B (zh) | 2014-02-13 | 2016-09-07 | 武汉珈瑜科技有限公司 | 用于制备suvorexant的化合物及其制备方法 |
| JP6737708B2 (ja) | 2014-04-17 | 2020-08-12 | サンド・アクチエンゲゼルシヤフト | オレキシン受容体拮抗薬を含む固体分散体 |
| WO2015164160A1 (en) | 2014-04-21 | 2015-10-29 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
| WO2015180060A1 (zh) | 2014-05-28 | 2015-12-03 | 杭州普晒医药科技有限公司 | 一种二氮杂环庚烷化合物的盐及其晶型与无定型物 |
-
2013
- 2013-05-29 RU RU2014152031A patent/RU2699358C2/ru active
- 2013-05-29 AU AU2013267613A patent/AU2013267613A1/en not_active Abandoned
- 2013-05-29 US US14/404,147 patent/US10098892B2/en active Active
- 2013-05-29 BR BR112014025041A patent/BR112014025041B8/pt active IP Right Grant
- 2013-05-29 KR KR1020147033238A patent/KR102123130B1/ko active IP Right Grant
- 2013-05-29 WO PCT/US2013/042959 patent/WO2013181174A2/en active Application Filing
- 2013-05-29 EP EP13796870.7A patent/EP2854816B1/en active Active
- 2013-05-29 MX MX2014014644A patent/MX368859B/es active IP Right Grant
- 2013-05-29 CN CN201380028103.2A patent/CN104321059A/zh active Pending
- 2013-05-29 JP JP2015515118A patent/JP6263169B2/ja active Active
- 2013-05-29 CN CN201811196847.6A patent/CN109078015A/zh active Pending
- 2013-05-29 RU RU2019126797A patent/RU2759837C2/ru active
-
2018
- 2018-02-22 AU AU2018201279A patent/AU2018201279B2/en active Active
- 2018-08-09 US US16/059,439 patent/US11160811B2/en active Active
-
2021
- 2021-09-14 US US17/474,322 patent/US11980623B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX368859B (es) | 2019-10-18 |
| EP2854816A4 (en) | 2015-10-28 |
| AU2018201279A1 (en) | 2018-03-15 |
| AU2013267613A1 (en) | 2014-10-02 |
| RU2759837C2 (ru) | 2021-11-18 |
| RU2019126797A (ru) | 2019-10-07 |
| WO2013181174A2 (en) | 2013-12-05 |
| CN104321059A (zh) | 2015-01-28 |
| RU2699358C2 (ru) | 2019-09-05 |
| JP2015518867A (ja) | 2015-07-06 |
| BR112014025041B8 (pt) | 2023-04-18 |
| US10098892B2 (en) | 2018-10-16 |
| BR112014025041B1 (pt) | 2019-10-22 |
| EP2854816A2 (en) | 2015-04-08 |
| CN109078015A (zh) | 2018-12-25 |
| KR102123130B1 (ko) | 2020-06-15 |
| US20190038635A1 (en) | 2019-02-07 |
| US20150190402A1 (en) | 2015-07-09 |
| EP2854816B1 (en) | 2020-07-08 |
| KR20150014940A (ko) | 2015-02-09 |
| JP6263169B2 (ja) | 2018-01-17 |
| MX2014014644A (es) | 2015-02-12 |
| AU2018201279B2 (en) | 2019-11-21 |
| RU2014152031A (ru) | 2016-07-20 |
| US11160811B2 (en) | 2021-11-02 |
| US11980623B2 (en) | 2024-05-14 |
| US20220062295A1 (en) | 2022-03-03 |
| WO2013181174A3 (en) | 2014-01-30 |